Allogene Therapeutics, Inc. (ALLO)

$3.46

+0.1

(+2.98%)

Live

Insights on Allogene Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 52.0K → 44.0K (in $), with an average decrease of 15.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -98.33M → -77.98M (in $), with an average increase of 26.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 161.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 165.8% return, outperforming this stock by 256.7%

Performance

  • $3.37
    $3.50
    $3.46
    downward going graph

    2.6%

    Downside

    Day's Volatility :3.71%

    Upside

    1.14%

    downward going graph
  • $3.36
    $12.21
    $3.46
    downward going graph

    2.89%

    Downside

    52 Weeks Volatility :72.48%

    Upside

    71.66%

    downward going graph

Returns

PeriodAllogene Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-26.8%
-0.9%
0.0%
6 Months
-33.2%
1.5%
1.0%
1 Year
-70.16%
7.1%
6.4%
3 Years
-90.98%
25.9%
19.9%

Highlights

Market Capitalization
678.9M
Book Value
$3.73
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.54
Wall Street Target Price
16.93
Profit Margin
0.0%
Operating Margin TTM
-186693.24%
Return On Assets TTM
-26.07%
Return On Equity TTM
-49.79%
Revenue TTM
192.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-48.8%
Gross Profit TTM
243.0K
EBITDA
-344.4M
Diluted Eps TTM
-2.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.24
EPS Estimate Next Year
-2.2
EPS Estimate Current Quarter
-0.59
EPS Estimate Next Quarter
-0.56

Analyst Recommendation

Buy
    80%Buy
    16%Hold
    4%Sell
Based on 25 Wall street analysts offering stock ratings for Allogene Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
21
21
Hold
4
4
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 389.31%

Current $3.46
Target $16.93

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
-11.11%
-33.2%
-70.16%
-90.98%
-86.56%
Moderna, Inc.
Moderna, Inc.
-13.8%
-33.86%
-19.73%
39.08%
427.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.18%
1.46%
19.77%
45.55%
105.03%
Novo Nordisk A/s
Novo Nordisk A/s
-2.09%
18.67%
91.43%
165.4%
285.43%
Seagen, Inc.
Seagen, Inc.
4.8%
8.3%
59.7%
13.46%
176.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
14.01%
23.51%
31.36%
85.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
NA
NA
NA
-2.24
-0.5
-0.26
0.0
3.73
Moderna, Inc.
Moderna, Inc.
35.31
35.31
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.99
42.99
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.12
27.12
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.
Buy
$678.9M
-86.56%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.4B
427.53%
35.31
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
105.03%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$407.6B
285.43%
42.99
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
176.24%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.8B
85.35%
27.12
35.4%

Institutional Holdings

  • FMR Inc

    14.87%
  • TPG GP A, LLC

    11.17%
  • State Street Corporation

    5.06%
  • BlackRock Inc

    5.04%
  • Vanguard Group Inc

    4.48%
  • JPMorgan Chase & Co

    3.66%

Corporate Announcements

  • Allogene Therapeutics, Inc. Earnings

    Allogene Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le

Organization
Allogene Therapeutics, Inc.
Employees
359
CEO
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.
Industry
Health Technology

FAQs